Matt McNally, CEO of Outcome Health, shares his thoughts on post-controversy Outcome Health and the overall state of the point-of-care union.
Among the group's members are media agencies that had pulled healthcare ad spend from the POC channel in the wake of a scandal 10 months ago.
After a scandal with one of point of care's biggest players, we examine how the community is living up to its promise of greater transparency.
Azar says HHS can eliminate rebates; States pass measures to stop drug price increases; 'Poor oversight' blamed for California sitting on cash to treat mentally ill.
Purdue Pharma taps financial restructuring firm; White House wants opioid-production cut; NYU to make med school free.
For Gideon, honoring those who helped build the medical ad industry became a labor of love.
Teva's generic EpiPen injector received a thumbs up from the FDA on Thursday.
The study estimated the FDA's anti-smoking campaign, The Real Cost, saved $31 billion in smoking-related costs to society.
CDC estimates 72,000 died of drug overdoses in 2017; Genentech to lay off 200-plus employees; Pfizer invests up to $425 million in BioNTech.
Alphabet invests more in Oscar; ViiV's HIV injection proves effective; Gilead's chief medical officer departs in latest executive exit.
Moosmayer is set to join the pharma company in December.
Bigger budgets, fewer accounts. That's the dilemma facing pharma marketers as drugmakers consolidate work.
Icahn drops bid to stop Cigna-Express Scripts tie-up; Bayer joins Evotec-Haplogen partnership to find COPD treatments; Orchard raises $150 million in Series C funding.